Weight loss study testing a new drug alone or with tirzepatide
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests an experimental drug called RN3161 to see if it helps with weight loss in people with overweight or obesity. It can be taken alone or with another weight-loss medication (tirzepatide).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with a body mass index (BMI) of 30 or higher (or 27.5 if you are of Asian ancestry) or a BMI of 27–30 (23–27.5 if Asian ancestry) plus a weight-related health issue like high blood pressure, high cholesterol, or osteoarthritis
- Your weight has been stable (no more than 5% change) in the last 3 months
- You have not taken any GLP-1 medications (like Wegovy or Ozempic) in the past 6 months
- You have not had any bad reactions to GLP-1 medications before
- You have not taken any other weight-loss drugs in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two drugs, NA-931 and tirzepatide, to see if they are safe and help adults who are overweight or obese lose weight. You may qualify if you have a high body mass index (BMI) and have tried to lose weight before without lasting success.
This trial examines how well tirzepatide works for weight loss in people with obesity, and how it's actually used in daily life. It may be an option if you haven't tried other obesity treatments and don't have diabetes.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This trial tests whether an experimental drug (LY3437943) can help people with obesity or overweight lose weight. It compares the drug to a placebo (inactive shot), and you must be willing to give yourself daily injections.
This trial tests if the weight loss medication tirzepatide can help young adults (18–40) with obesity and high blood pressure lower their blood pressure. It compares standard care to weight loss with tirzepatide.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
Hear when a new Obesity &Amp; Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.